AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014Seeking Alpha • 10/16/23
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary EndpointsPRNewsWire • 10/15/23
Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks.The Motley Fool • 10/12/23
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3PRNewsWire • 10/12/23
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic DermatitisPRNewsWire • 10/11/23
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023PRNewsWire • 10/10/23
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience PipelinePRNewsWire • 10/05/23
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer ImmunotherapyPRNewsWire • 10/04/23
3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 YearsThe Motley Fool • 10/04/23